CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 682 enrolled
Drug / intervention
intravitreal triamcinolone injection +2 moredrug
Likely dose
Intravitreal triamcinolone acetonide 1 mg or 4 mg injectionAI-extracted
Key inclusion· 2
  • Macular edema associated with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO)
  • Age 18 years or older
Key exclusion· 1
  • Exclusion criteria not fully detailed in this record; refer to SCORE Study website

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00105027
NCT00105027Phase 3Completed

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema

The Emmes Company, LLC·interventional·Posted Mar 4, 2005·Updated Jul 2, 2018

In Brief

A Phase 3 clinical trial evaluating Standard Care and intravitreal triamcinolone injection for Macular Edema, Cystoid and Retinal Vein Occlusion. Completed, enrolled 682 participants across 1 site.

Detailed Summary

The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 4, 2005
Enrollment StartOct 1, 2004
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 21.3 years ago

Interventions

Standard Careother

CRVO: observation; BRVO: standard care

intravitreal triamcinolone injectiondrug

1 mg dose

intravitreal triamcinolone injectiondrug

4 mg